Format

Send to

Choose Destination
See comment in PubMed Commons below
PLoS One. 2014 Apr 9;9(4):e94231. doi: 10.1371/journal.pone.0094231. eCollection 2014.

Rapid and efficient conversion of integration-free human induced pluripotent stem cells to GMP-grade culture conditions.

Author information

1
Institute for Stem Cell Biology and Regenerative Medicine, Department of Obstetrics and Gynecology and Department of Genetics, Stanford University, Stanford, California, United States of America.
2
Eli and Edythe Broad Center for Regenerative Medicine & Stem Cell Research, University of California Los Angeles, Los Angeles, California, United States of America; Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California, United States of America.
3
Eli and Edythe Broad Center for Regenerative Medicine & Stem Cell Research, University of California Los Angeles, Los Angeles, California, United States of America; Department of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, Los Angeles, California, United States of America.
4
Veterans Affairs Palo Alto Health Care System, Stanford University, Palo Alto, California, United States of America.
5
Eli and Edythe Broad Center for Regenerative Medicine & Stem Cell Research, University of California Los Angeles, Los Angeles, California, United States of America; Department of Molecular, Cellular, and Developmental Biology, Molecular Biology Institute, University of California Los Angeles, Los Angeles, California, United States of America.
6
Stanford Cardiovascular Institute, Stanford University, Stanford, California, United States of America; Department of Cardiology, Department of Medicine, Stanford University, Stanford, California, United States of America.
7
Department of Developmental Biology, Stanford University, Stanford, California, United States of America.

Abstract

Data suggest that clinical applications of human induced pluripotent stem cells (hiPSCs) will be realized. Nonetheless, clinical applications will require hiPSCs that are free of exogenous DNA and that can be manufactured through Good Manufacturing Practice (GMP). Optimally, derivation of hiPSCs should be rapid and efficient in order to minimize manipulations, reduce potential for accumulation of mutations and minimize financial costs. Previous studies reported the use of modified synthetic mRNAs to reprogram fibroblasts to a pluripotent state. Here, we provide an optimized, fully chemically defined and feeder-free protocol for the derivation of hiPSCs using synthetic mRNAs. The protocol results in derivation of fully reprogrammed hiPSC lines from adult dermal fibroblasts in less than two weeks. The hiPSC lines were successfully tested for their identity, purity, stability and safety at a GMP facility and cryopreserved. To our knowledge, as a proof of principle, these are the first integration-free iPSCs lines that were reproducibly generated through synthetic mRNA reprogramming that could be putatively used for clinical purposes.

PMID:
24718618
PMCID:
PMC3981795
DOI:
10.1371/journal.pone.0094231
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Publication types

MeSH terms

Substances

Grant support

PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Support Center